Report #2847152

Received Jun 25, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: LA
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	IM

Symptoms (1)

Interchange of vaccine products

Symptom narrative

First Dose Received HEPLISAV-B and Second Dose ENGERIX-B; Initial report received on 04-Jun-2025. A nurse reported that a patient (age and gender not reported) received HEPLISAV-B (hepatitis B vaccine) as the first dose of hepatitis B immunization and the second dose received was ENGERIX-B. No medical history or concomitant medications were reported. On an unknown date, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available)]. On an unknown date, after having been vaccinated with HEPLISAV-B, the patient received the second dose of hepatitis B vaccine [ENGERIX-B (lot number and expiration date not reported)]. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Other medications

Engerix-b